![Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer](https://oncodaily.com/pub/uploads/2024/02/download-29-e1710180869983.jpg)
Photo taken from Elisa Agostinetto/LinkedIn
May 20, 2024, 11:18
Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn:
“Now out in Cell Reports Medicine, our review on emerging treatments for HER2+ breast cancer.
We discuss how survival improvements in this disease set a high bar for new drug development and the need to explore new ways to overcome resistance mechanisms.”
Additional information.
Source: Elisa Agostinetto/LinkedIn